Actinic Keratosis Market

Actinic Keratosis Market - Global Industry, Analysis, Size, Share, Growth, Trends, and Forecasts 2023-2030

Actinic keratosis, sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of thick, scaly, or crusty skin that feels dry or rough. Size commonly ranges between 2 and 6 millimeters, but they can grow several centimeters in diameter. Actinic keratosis is a disorder of epidermal keratinocytes that is induced by ultraviolet light exposure. Given the causal relationship between sun exposure and actinic keratosis growth, these growths are more common in fair-skinned people and those who are frequently in the sun. That occurs on the face, ears, neck, scalp, chest, backs of hands, forearms, or lips. Because sun exposure is rarely limited to small areas, most people who an actinic keratosis have more than one. They are believed to be formed when skin gets damaged by UV radiation from the sun or indoor tanning beds, usually over decades. Given their precancerous nature, if left untreated, they may turn into a type of skin cancer called squamous cell carcinoma. Untreated lesions have up to a 20% risk of progression to squamous cell carcinoma.

Actinic keratosis is most commonly present as a white, scaly plaque of variable thickness with surrounding redness. The skin near the lesion often shows evidence of solar damage characterized by notable pigmentary alterations. The lesions are usually asymptomatic but can be tender, itch, bleed, or produce a stinging or burning sensation. Actinic keratosis is graded by their clinical presentation: Grade I (easily visible, slightly palpable), and Grade III (frankly visible and hyperkeratotic). At present, the considerably expanding healthcare infrastructure and increasing need for preventive strategies for cancer are positively influencing the demand for actinic keratosis treatment worldwide.

Global Actinic Keratosis Market – Competitive Landscape

In the market of actinic keratosis, there have been several mergers, collaborations, and competitive developments. In April 2020, Bio Frontera signed an exclusive agreement with Maruho Co.Ltd. in Japan for the development and commercialization of Ameluz, a medicine used in adults to treat mild to moderate actinic keratosis. Many companies have been working on developing topical therapies and creams for the treatment of actinic keratosis.

Some of the key players in the actinic keratosis market include –

  • Leo Pharma
  • Galderma
  • Bausch Health Companies
  • Bio Frontera
  • Sun pharmaceutical industry
  • Ferndale Pharmaceutical

Global Actinic Keratosis Market – Growth Drivers

The developments of more effective and patient-friendly treatment options for actinic keratosis by different companies such as topical therapies, cryotherapy, and photodynamic therapy have expanded the market. Different technological advances, such as teledermatology, and the use of mobile applications for skin monitoring, have improved the accessibility of care and contributed to market growth. The actinic keratosis market has several key areas that require meticulous attention and analysis to gain valuable insights and facilitate informed decision-making. Market size and growth, market share analysis, and industry drivers these focal points are crucial for businesses and stakeholders seeking a comprehensive understanding of the actinic keratosis market dynamics and potential growth opportunities. Some companies are focused on actinic keratosis Global Day 2023 to raise awareness of actinic keratosis.

Global Actinic Keratosis Market – Restraint

Regulatory approval for new treatments and therapies can be time-consuming as it requires more time to the introduction of innovative actinic keratosis management options. There are different healthcare treatments for actinic keratosis which are associated with high costs which is a burden on healthcare systems and individuals, especially in the absence of insurance coverage. According to National Center for Biotechnology Information (NCBI), annual actinic keratosis treatment costs of US$ 52 Million to US$ 59 million per year. Varying insurance coverage for actinic keratosis treatment may affect patient access to therapies. The healthcare resources for dermatological care are limited in some regions which affects the patient access to healthcare specialists. Also, there is no any kind of specific treatment for actinic keratosis which is universally accepted therefore it leaving a gap in the availability of effective drug therapies.

Global Actinic Keratosis Market – Opportunities

Marketing of different advanced topical therapies with improved efficacy and reduced side effects for actinic keratosis management. Expanding telehealth and teledermatology services for actinic keratosis diagnosis, monitoring, and consultation, especially in underserved areas. Investigating a combination of existing actinic keratosis treatments to improve patient outcomes. Entering emerging markets with increasing skincare cancer rates, creating opportunities for actinic keratosis focused products and services.

Global Actinic Keratosis Market – Geographical Insight

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, Europe and Africa. Actinic market growth will originate from North America, the largest actinic keratosis market during the forecast period, which is the key market for actinic keratosis, due to the high prevalence of actinic keratosis in the region, increasing healthcare expenditure, and the presence of major market players. Market growth in these regions will be faster than the growth of the market in Europe, Asia-Pacific, and Row. Europe is the second-largest market, while the Asia-Pacific region is expected to witness the highest growth rate during the forecast period due to increasing awareness about actinic keratosis and the growing geriatric population.

Global Actinic Keratosis Market – Key Development

  • On October 10, 2023, Bio Frontera a biopharmaceutical company received the approval from U.S.Food and Drug Administration for a new formulation of Ameluz® (Aminolevulinic acid hydrochloride ) for the treatment of actinic keratosis and production of this product beginning in 2024.
  • In 2021 the Nordic Biotech Coegin Pharma started clinical evaluation of its candidate AVX001 as a potential new and better treatment for actinic keratosis.
  • In December 2020, Almirall received FDA approval for Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis.
Complete the form below and we'll get back to you shortly
Table of Content
Complete the form below and we'll get back to you shortly
cognizance market research(cmr)

Actinic Keratosis Market


Black Friday Offers (40% Off)​

Don’t Miss Out On The Biggest Savings Of The Year!

- Get Started -

Get insights that lead to new growth opportunities

Need a Custom Report?

We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Business Development

small c popup.png

Black Friday Offers (40% Off)

Don't miss out on the biggest savings of the year!

small c popup.png
Buy Now
small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
Ask an Expert